Merck & Co, AstraZeneca and Alexion are all in line for exits after Moderna Therapeutics, valued at $7.5bn earlier this year, filed for its initial public offering.
US-based vaccine developer Moderna Therapeutics has filed to raise up to $500m in an initial public offering that would enable pharmaceutical firms Merck & Co, AstraZeneca and Alexion Pharmaceuticals to exit.
Founded in 2010, Moderna is working on vaccines and drugs based on messenger RNA and it has a pipeline of 21 product candidates with development partners, 10 of which have reached the clinical testing stage.
Proceeds from the IPO, which is set to take place on the Nasdaq…
